A term without a definition
“Micro dosing” has moved from other fields into the conversation about GLP-1 medications, and it arrived without a definition. When people use it about semaglutide or tirzepatide they usually mean one of three things: a dose lower than the maintenance doses the FDA-approved labels describe, a dose lower than the labels’ starting doses, or staying at a low dose for much longer than the label schedule before moving up, or without moving up at all. Sometimes they mean all three. None of those is a term the labels use.
This guide explains what the labels actually describe, why the evidence for lower dosing is limited, and how Bodi Envi’s lower dose programs are structured. It does not contain a chart of doses, and the reason is set out below. This is general information and not medical advice. The labels and trials discussed describe the FDA-approved products, not compounded versions, and your licensed provider is the person to ask about your own dose.
What the labels describe
The Wegovy® prescribing information describes a starting dose of 0.25 mg once weekly for four weeks, steps to 0.5 mg, 1 mg and 1.7 mg at four week intervals, and a maintenance dose from week seventeen of 1.7 mg or 2.4 mg for weight reduction in adults, with a further increase to 7.2 mg described for some patients. The Zepbound® label describes a starting dose of 2.5 mg once weekly for four weeks, then 5 mg, then increases of 2.5 mg after at least four weeks on a dose, with 5 mg, 10 mg and 15 mg as the maintenance doses for weight reduction. The Zepbound® label states in so many words that the 2.5 mg dose is for treatment initiation and is not approved as a maintenance dose.
Both labels give one reason for starting low: to reduce the risk of gastrointestinal adverse reactions. Both allow a provider to slow the escalation, and the Zepbound® label says that if a maintenance dose is not tolerated a lower maintenance dose should be considered, with 5 mg the lowest it lists. What neither label describes is a dose below its starting dose, a starting dose used as a maintenance dose, or a plan in which the dose never rises. Those are the things people usually mean by micro dosing, and on the FDA-approved documents they are simply absent.
That absence is not a prohibition and it is not an endorsement. It means the manufacturer did not study those arrangements in the trials that supported approval, and the FDA did not review them. Anyone describing a lower dose plan as label supported is mistaken.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
What the trials studied for the brand name products
The evidence behind these medications for weight management comes from trials of the labelled doses. STEP 1, published in the New England Journal of Medicine in 2021, gave 1,961 adults either 2.4 mg of semaglutide once weekly or placebo for 68 weeks and reported a mean body weight change of 14.9 percent against 2.4 percent. SURMOUNT-1, published in the same journal in 2022, gave 2,539 adults 5 mg, 10 mg or 15 mg of tirzepatide once weekly or placebo for 72 weeks and reported mean changes of 15.0, 19.5 and 20.9 percent against 3.1 percent. Both studied the branded products alongside a reduced calorie diet and increased physical activity.
SURMOUNT-1 is the closer of the two to a dose comparison, and its result at 5 mg, the lowest labelled maintenance dose, was smaller than at 10 mg and 15 mg. That is a finding about three labelled doses of Zepbound®, not about doses below them. Neither trial studied a dose below the label’s starting dose, and neither studied a plan that stayed at a low dose. This guide has found no peer reviewed trial of comparable size that has. The evidence for lower dosing is therefore limited to small studies, observational reports and clinical experience, none of which this site treats as a basis for a claim about what a lower dose does.
The trials also do not describe what a lower dose does to side effects beyond the escalation phase. The labels report that gastrointestinal reactions occur most during escalation and decrease over time, and the FDA’s concerns statement notes adverse events in patients given doses beyond the label; neither says anything about a dose held below it. The trials were completed with the brand name product, and the personalized compounded product will not produce the same results as the brand name product; the personalized compounded product is a completely different product. This is for educational purposes only, and the studies above apply only to the brand name versions.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
Why there is no chart here
A dosage chart on this site would need a source. For the labelled schedules that source exists, and the guide to the Wegovy® schedule on this site reproduces it. For lower doses there is no FDA-approved label and no large trial to take numbers from, so a table of micro doses would present figures with no established basis as though they were settled, and it would function as dosing advice, which this site does not give. The FDA’s statement on unapproved GLP-1 drugs, dated September 1, 2026, reports hospitalizations linked to dosing errors with personalized compounded semaglutide and asks providers to be vigilant about doses and titration; a chart that invited readers to set their own low dose would run directly against that.
The only doses this site reports are the ones the labels state, and it reports them as descriptions of the branded products rather than as instructions.
What the label warnings say about dose
People sometimes assume a lower dose sits outside the labels’ warnings. It does not. The boxed warning about thyroid C-cell tumours, the contraindications for a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 and for serious hypersensitivity, and the warnings about pancreatitis, gallbladder disease, low blood sugar with insulin or a sulfonylurea, kidney injury from dehydration and the rest apply to the medication, not to a particular strength. The Wegovy® label’s pregnancy section says to discontinue the medication at least two months before a planned pregnancy because of its long half-life, and the Zepbound® label’s advice about oral contraceptives is tied to starting the medication and to each dose increase. A provider weighing a lower dose weighs all of that in the same way.
What a lower dose plausibly does, given the labels’ statement that escalation exists to reduce gastrointestinal reactions, is keep a person in the range where those reactions are least frequent. Whether that trade is right for an individual, and at what dose, is a clinical judgment, and this guide does not make it.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
How Bodi Envi’s lower dose programs work
Bodi Envi’s published list of programs, in its machine readable summary, includes micro-dose personalized compounded semaglutide programs and micro-dose personalized compounded tirzepatide programs alongside its standard programs. Its treatment pages describe each as a provider-guided lower dose personalized compounded program for eligible patients, based on individual clinical evaluation. The structure is the same as for every Bodi Envi program: an online health assessment, review by a licensed provider through Wasef Health, PC for applicable programs, a prescription only if that provider determines treatment is appropriate, and dispensing by a third party U.S. 503A licensed compounding pharmacy.
Three things follow from that. The provider decides the dose. A lower dose program is not a dose you select; it is a program a licensed provider may consider appropriate for you after evaluation, and the provider sets the starting dose, the timing of any change, and whether the dose rises at all. The pharmacy label governs measuring. Compounded medication typically comes as a vial measured with a syringe, and the concentration and instructions on the pharmacy label are the only correct conversion for your vial. And the medication is compounded. Personalized Compounded semaglutide and tirzepatide are not FDA-approved, the FDA does not review them for safety, effectiveness or quality before they are marketed, and they are not equivalent to the approved products; the trials above did not study them at any dose.
Bodi Envi publishes that, for applicable programs, pricing does not increase based solely on dosage strength. For a lower dose program that cuts both ways: staying at a low dose does not reduce the price, and moving up does not raise it, so the dose decision stays clinical.
What to ask your provider
If you are interested in a lower dose approach, the useful questions are about reasoning rather than numbers. Why a lower dose might suit your history and goals. What the provider expects to watch for, and over what period, before deciding whether to hold or change the dose. How the plan compares with the label schedule, and why it differs where it does. What to do if side effects appear or if they do not. And what the plan is for reviewing the decision, since the labels describe treatment in terms of months rather than weeks.
Whatever the answer, it comes from a licensed provider with your assessment in front of them, and it is not something this guide or any chart can supply. This is general information and not medical advice, the evidence for lower dosing is limited and the trials cited studied the branded products at their labelled doses, and your provider is the person to ask.